Related Experiment Video

Updated: Jul 14, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced

John T Parissis1, Apostolos Karavidas, Vassiliki Bistola

  • 1Second Department of Cardiology, Attikon University Hospital, Rimini 1, 12461 Chaidari, Athens, Greece. jparissis@yahoo.com <jparissis@yahoo.com>

Atherosclerosis
|June 15, 2007
PubMed

Insights

Levosimendan improved endothelial function and reduced adhesion molecules in advanced chronic heart failure (CHF) patients. This calcium sensitizer offers a potential treatment to mitigate CHF progression by enhancing vascular health.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Pharmacology

Background:

  • Endothelial dysfunction is a key factor in chronic heart failure (CHF) progression.
  • Elevated soluble adhesion molecules contribute to CHF pathophysiology.
  • Targeting endothelial activation may offer therapeutic benefits in advanced CHF.

Purpose of the Study:

  • To investigate the effect of levosimendan on endothelial function in advanced CHF patients.
  • To assess whether levosimendan can reduce plasma levels of soluble adhesion molecules (sICAM-1 and sVCAM-1).
  • To evaluate the potential of levosimendan in attenuating deleterious effects in advanced CHF.

Main Methods:

  • Randomized controlled trial with 26 advanced CHF patients.
  • Intervention: 24-hour infusion of levosimendan (n=17) or placebo (n=9).
  • Outcome measures: Flow-mediated dilatation (FMD) for endothelial function, plasma sICAM-1 and sVCAM-1 levels assessed pre- and post-therapy.

Main Results:

  • Levosimendan significantly improved FMD (p<0.05).
  • Levosimendan treatment led to a significant reduction in plasma sICAM-1 and sVCAM-1 levels (p<0.05).
  • No significant changes in FMD or adhesion molecules were observed in the placebo group.

Conclusions:

  • Levosimendan demonstrates efficacy in improving endothelial function in advanced CHF.
  • The drug effectively reduces detrimental adhesion molecule activation in this patient population.
  • Levosimendan represents a promising therapeutic option for managing endothelial dysfunction in advanced CHF.
Abstract

More Related Videos

Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels08:46

Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels

Published on: March 22, 2024

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...